Bristol Myers Squibb, shared on LinkedIn:
“Today, we announced topline results from a Phase 3 trial for our investigational medicine for adults living with idiopathic pulmonary fibrosis (IPF).
People living with IPF continue to face significant challenges, highlighting the ongoing need for new therapeutic options.
These results represent an important milestone and reinforce our commitment to advancing science for this community.
We’re grateful to the patients, caregivers and investigators whose contributions made this research possible.”
You may also be interested in: RYZ101 Improves PFS in Phase 3 ACTION-1 Trial for GEP-NETs After Lutetium-177 Therapy
